NVO: 6-K company filing

6-K 1 f6k_060826.htm FORM 6-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ________________ FORM 6-K ________________ REPORT OF FOREIGN PRIVATE ISSUER Pursuant to Rule 13a-16 or 15d-16 of the Securities Exchange Act of 1934 June 8, 2026 ________________ NOVO NORDISK A/S (Exact name of Registrant as specified in its charter) Novo Allé 1 DK- 2880, Bagsvaerd Denmark (Address of principal executive offices) ________________ Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F Form 20-F ☒ Form 40-F ☐ Novo Nordisk A/S – Share repurchase programme Bagsværd, Denmark, 8 June 2026 – On 6 May 2026, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 15 billion to be executed during a 12-month period beginning 4 February 2026. Under the programme initiated 6 May 2026, Novo Nordisk will repurchase B shares for an amount up to DKK 11,200,000,010.45 in the period from 6 May 2026 to 1 February 2027. Since the announcement 1 June 2026, the following transactions have been made: Number of B shares Average purchase price Transaction value, DKK Accumulated, last announcement 3,130,000 913,270,696 1 June 2026 210,000 292.91 61,512,149 2 June 2026 210,000 280.05 58,810,689 3 June 2026 225,000 276.91 62,305,652 4 June 2026 225,000 278.01 62,553,306 Accumulated under the programme 4,000,000 1,158,452,492 The details for each transaction made under the share repurchase programme are published on n